L
Leon Stutzman
Researcher at Roswell Park Cancer Institute
Publications - 17
Citations - 430
Leon Stutzman is an academic researcher from Roswell Park Cancer Institute. The author has contributed to research in topics: Chemotherapy & Vincristine. The author has an hindex of 10, co-authored 17 publications receiving 425 citations.
Papers
More filters
Journal Article
Second malignant neoplasms in patients successfully treated for Hodgkin's disease: a Cancer and Leukemia Group B study.
Journal Article
Chemotherapy and combined modality therapy for Hodgkin's disease: a progress report on Cancer and Leukemia Group B studies.
Clara D. Bloomfield,Thomas F. Pajak,A S Glicksman,A J Gottlieb,Morton Coleman,Nis I. Nissen,S Rafla,Leon Stutzman,V Vinciguerra,Oliver Glidewell,James F. Holland +10 more
TL;DR: Between 1974 and 1977, the Cancer and Leukemia Group B initiated four studies which address current major questions in the therapy for Hodgkin's disease, finding that relapse-free and overall survival is better with the doxorubicin-containing regimen than with either the alternating or alternate chemotherapy program.
Journal ArticleDOI
Pharmacologic effects of polyinosinic• polycytidylic acid in man
Arnold I. Freeman,Nazar Al‐Bussam,Judith A. O'Malley,Leon Stutzman,Sigurdur Bjornsson,William A. Carter +5 more
TL;DR: Patients with cancer and concomitant infections with either herpes virus hominis or varicella zoster virus were treated with polyinosinic·polycytidylic acid to determine the reliability of rIn·rCn to induce interferon production, and the toxicity of the drug.
Journal ArticleDOI
A comparative study of a bcnu containing 4‐drug program versus mopp versus 3‐drug combinations in advanced Hodgkin's disease. A cooperative study by the cancer and leukemia group B
Nis I. Nissen,Thomas F. Pajak,Oliver Glidewell,Jens Pedersen‐Bjergaard,Leon Stutzman,Geoffrey Falkson,Janet Cuttner,Johannes Blom,Louis A. Leone,Arthur Sawitsky,Morton Coleman,Farid I. Haurani,Charles L. Spurr,John B. Harley,Barbara Seligman,Cornelius J. Cornell,Patrick H. Henry,Senn Hj,Kurt Brunner,George Martz,Pierre Maurice,Arthur Bank,Lorne Shapiro,G. Watson James,James F. Holland +24 more
TL;DR: A prospective randomized trial by CALGB examined the relative value of four chemotherapy regimens in 537 patients with stage III B and IV Hodgkin's disease, finding that a new combination BOPP had a therapeutic activity equal to MOPP, and was accompanied by less toxicity.
Journal ArticleDOI
Alternating cycles of combination chemotherapy for patients with recurrent Hodgkin's disease following radiotherapy. A prospectively randomized study by the Cancer and Leukemia Group B.
Vincent Vinciguerra,Kathleen J. Propert,Morton Coleman,James R. Anderson,Leon Stutzman,Thomas F. Pajak,Nis I. Nissen,Glauco Frizzera,Arlan J. Gottlieb,J F Holland +9 more
TL;DR: This study demonstrates no statistically significant advantage for alternating cycles of combination chemotherapy in affecting complete response frequency, disease-free survival, or overall survival as compared with therapy with CVPP or ABOS alone.